NEWPORT NEWS, Va. (November 21, 2013)  Blue Cross Blue Shield of Arizona (BCBS AZ) covers the use of TheraSkin®, a clinically-proven living cell therapy for a wide range of non-performing and acute wounds,  including diabetic foot, venous leg ulcers, pressure ulcers and other wounds that might otherwise require an autograft.

“This coverage is important for the nearly 1.3 million Arizonians who count on BCBS AZ for health care coverage,” said Thomas “Kerry” McCarter, CEO of Soluble Systems LLC, which markets TheraSkin. The mission of BCBS AZ –“providing the best value in health insurance and quality of life for those it serves”—is strongly supported by Soluble Systems, and the two organizations are a “good fit,” said McCarter. With TheraSkin, patients covered by BCBS AZ will enjoy excellent healing results at much lower cost than available today from bio-engineered, biologically active therapies.

Diabetics in the BCBS AZ system will particularly benefit from TheraSkin. Arizona, like the rest of the U.S., has experienced a major increase in the percentage of adults who are diabetic and is currently home to an estimated 600,000 adults with Type 2 diabetes.

“Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60 percent of previously “non-healing” diabetic ulcers in 12 weeks.

TheraSkin is not only clinically effective, but economical, costing 50 to 70 percent less than competing biologically active products, saving patients and payers thousands of dollars per treatment. A potent weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the nation’s healthcare system more than $1 billion over the next decade.

“We will work tirelessly with the medical institutions and practitioners in Arizona to help implement the clinical and economic benefits of TheraSkin,” added Allan Staley, President of Soluble Systems.

For more information on BCBS AZ coverage, visit

About TheraSkin®

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing.